European approval for Guidant's heart device:
This article was originally published in Clinica
Executive Summary
Guidant has CE-marked for sale in Europe its latest cardiac resynchronisation therapy defibrillator (CRT-D), the Contak Renewal 4. Claimed to be the thinnest CRT-D available, the implantable device contains additional enhancements on previous Renewal versions, including a high energy option for larger hearts that require more power to restore normal rhythm and HRV Monitor Footprint technology. This which allows visualisation of patient heart rate over time. Like previous versions, the device contains diagnostic sensing for customised therapy to the left and right ventricles. The firm announced that the first implantations of the Renewal 4 have taken place in Italy and Germany.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.